Home / Innere Medizin / Onkologie / ESMO 2019: NSCLC – «We now have many frontline treatment options to discuss with patients»
Breakfast Brief

ESMO 2019: NSCLC – «We now have many frontline treatment options to discuss with patients»

Prof. Solange Peters, MD, PhD, CHUV Lausanne, puts the research she presented at ESMO 2019 in perspective by explaining the complex CheckMate 227 trial and giving an update on the NICOLAS trial.

Cookies aktivieren

Um das Video anzusehen, müssen Sie Statistikcookies akzeptieren.

Einstellungen verwalten
References
  • Peters S et al. Nivolumab (NIVO) & low-dose ipilimumab (IPI) vs platinumdoublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis. #LBA4_PR
  • Peters S et al. Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial. #1457PD

ESMO Congress 2019

LOGIN

Login

Passwort vergessen?